Not yet recruitingPhase 2NCT05105958

Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Zurich
Principal Investigator
Annemarie Hübers
University Hospital, Geneva
Intervention
Tideglusib(drug)
Enrollment
98 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (5)

Collaborators

University of Lausanne Hospitals · University of Bern · Cantonal Hospital of St. Gallen · University Hospital, Geneva

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05105958 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials